Charles Zhou
Stock Analyst at Guggenheim
(1.51)
# 3,472
Out of 5,044 analysts
11
Total ratings
62.5%
Success rate
-1.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhou
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COGT Cogent Biosciences | Maintains: Buy | $17 → $20 | $16.09 | +24.30% | 2 | Aug 25, 2025 | |
| FUTU Futu Holdings | Maintains: Buy | $130 → $136 | $187.74 | -27.56% | 3 | Mar 17, 2025 | |
| ZYME Zymeworks | Reiterates: Buy | $16 | $19.30 | -17.10% | 1 | Mar 8, 2023 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.85 | - | 1 | May 5, 2022 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $56 | $1.47 | +3,709.52% | 1 | Aug 2, 2021 | |
| RPTX Repare Therapeutics | Initiates: Buy | $46 | $1.79 | +2,469.83% | 1 | Jun 28, 2021 | |
| QD Qudian | Downgrades: Neutral | n/a | $4.73 | - | 2 | Jan 22, 2020 |
Cogent Biosciences
Aug 25, 2025
Maintains: Buy
Price Target: $17 → $20
Current: $16.09
Upside: +24.30%
Futu Holdings
Mar 17, 2025
Maintains: Buy
Price Target: $130 → $136
Current: $187.74
Upside: -27.56%
Zymeworks
Mar 8, 2023
Reiterates: Buy
Price Target: $16
Current: $19.30
Upside: -17.10%
MacroGenics
May 5, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.85
Upside: -
PMV Pharmaceuticals
Aug 2, 2021
Initiates: Buy
Price Target: $56
Current: $1.47
Upside: +3,709.52%
Repare Therapeutics
Jun 28, 2021
Initiates: Buy
Price Target: $46
Current: $1.79
Upside: +2,469.83%
Qudian
Jan 22, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.73
Upside: -